pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
467
stories
May 6, 26
Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
onclive
May 6, 26
Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
onclive
May 6, 26
Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC
onclive
May 6, 26
Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
onclive
May 6, 26
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive
May 6, 26
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
onclive
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
May 6, 26
Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery
onclive
May 6, 26
Novo hikes guidance on Wegovy pill’s fast sales start
biopharma dive
May 6, 26
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
onclive
May 6, 26
Disease Assessment and Mutational Testing in Progressive CLL
onclive
May 6, 26
Clinical Scenario Presentation and Treatment Approach for Progressive Disease
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 6, 26
CellCentric raises $220M to get multiple myeloma pill to market
endpoints
May 6, 26
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
biopharma dive
May 5, 26
Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
onclive
May 5, 26
Dr Pant on Managing Toxicities With Daraxonrasib in PDAC
onclive
May 5, 26
Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
onclive
May 5, 26
The Type of Fat—Not the Amount—Fuels Pancreatic Cancer
onclive
May 5, 26
Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
onclive
May 5, 26
Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
onclive
May 5, 26
Vertex earnings get muted investor response
biopharma dive
May 5, 26
Coordinating Care in Multiple Myeloma Across Practice Settings
onclive
May 5, 26
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
endpoints
May 4, 26
UCB bets $2B on Candid's T cell engager ambitions
endpoints
May 1, 26
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
biopharma dive
May 1, 26
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
biopharma dive
May 1, 26
FDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal
endpoints
Apr 30, 26
FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
endpoints
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
← prev
page 15 of 16
next →
